Alison Taylor

Tennis Court Road
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

A prospective national precision medicine trial evaluating the feasibility of blood-based molecular profiling in patients with Cancer of Unknown Primary (CUP-COMP).

A prospective national precision medicine trial evaluating the feasibility of blood-based molecular profiling in patients with Cancer of Unknown Primary (CUP-COMP).

Journal: British journal of cancer

Published: September 30, 2025

Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma.

Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma.

Journal: International journal of cancer

Published: January 28, 2025

Editorial: Factors determining long term anti-tumor responses to immune checkpoint blockade therapy.

Editorial: Factors determining long term anti-tumor responses to immune checkpoint blockade therapy.

Journal: Frontiers in immunology

Published: December 09, 2022

Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolytic killing of melanoma cells.

Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolytic killing of melanoma cells.

Journal: Journal of hematology & oncology

Published: May 06, 2022

Non-redundant activity of GSK-3α and GSK-3β in T cell-mediated tumor rejection.

Non-redundant activity of GSK-3α and GSK-3β in T cell-mediated tumor rejection.

Journal: iScience

Published: January 29, 2021

Tumour cell CD99 regulates transendothelial migration via CDC42 and actin remodelling.

Tumour cell CD99 regulates transendothelial migration via CDC42 and actin remodelling.

Journal: Journal of cell science

Published: October 04, 2019

Small Molecule Inhibition of Glycogen Synthase Kinase-3 in Cancer Immunotherapy.

Small Molecule Inhibition of Glycogen Synthase Kinase-3 in Cancer Immunotherapy.

Journal: Advances in experimental medicine and biology

Published: October 03, 2019

Glycogen synthase kinase 3 (GSK-3) controls T-cell motility and interactions with antigen presenting cells.

Glycogen synthase kinase 3 (GSK-3) controls T-cell motility and interactions with antigen presenting cells.

Journal: BMC research notes

Published: September 14, 2019

Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity.

Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity.

Journal: Cell reports

Published: September 12, 2019

Commentary: Small Molecule Inhibition of PD-1 Transcription is an Effective Alternative to Antibody Blockade in Cancer Therapy.

Commentary: Small Molecule Inhibition of PD-1 Transcription is an Effective Alternative to Antibody Blockade in Cancer Therapy.

Journal: Journal of immunological sciences

Published: May 22, 2019

Withdrawal of treatment from critically ill children: legal and ethical issues.

Withdrawal of treatment from critically ill children: legal and ethical issues.

Journal: Nursing children and young people

Published: May 16, 2019

Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications.

Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications.

Journal: Seminars in immunology

Published: May 02, 2019

Showing 1-12 of 20

Last Updated: 09/26/2026